# Safety Study of Allogeneic Mesenchymal Precursor Cells (MPCs) in Subjects With Recent Acute Myocardial Infarction

> **NCT00555828** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Angioblast Systems** · enrollment: 25 (estimated)

## Conditions studied

- Myocardial Infarction

## Interventions

- **GENETIC:** Allogeneic Mesenchymal Precursor Cells (MPCs)
- **PROCEDURE:** Standard-of-care treatment with NOGA® mapping and staged injections.
- **GENETIC:** Allogeneic Mesenchymal Precursor Cells (MPCs)
- **PROCEDURE:** Standard-of-care treatment with NOGA® mapping and staged injections.
- **GENETIC:** Allogeneic Mesenchymal Precursor Cells (MPCs)
- **PROCEDURE:** Standard-of-care treatment with NOGA® mapping and staged injections.

## Key facts

- **NCT ID:** NCT00555828
- **Lead sponsor:** Angioblast Systems
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-03
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2010-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00555828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00555828, "Safety Study of Allogeneic Mesenchymal Precursor Cells (MPCs) in Subjects With Recent Acute Myocardial Infarction". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00555828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*